toralizumab toralizumab toralizumab (idec 131) was a humanized monoclonal antibody and an immunosuppressive drug. possible indications included treatment of antibody-mediated disorders (immune thrombocytopenic purpura, lupus nephritis, rheumatoid arthritis), t-cell-mediated diseases (multiple sclerosis, crohn's disease, and transplantations such as solid organ transplantation, pancreatic islet cell transplantation, and corneal transplantation), and b-cell malignancies such as cll/small lymphocytic lymphoma, follicular cell lymphoma grade i or ii, marginal zone lymphoma, mantle cell lymphoma, malt lymphoma, waldenström's macroglobulinemia, monocytoid b-cell lymphoma; relapsed/refractory hodgkin's disease). toralizumabmonoclonal antibodytypewhole antibodysourcehumanized (from mouse)targetcd40 ligandclinical dataatc codenoneidentifierscas number252662-47-8 nchemspidernoneuniikx44a9hm0bkeggd06193 y ny (what is this?) (verify) in phase ii clinical trials regarding multiple sclerosis and crohn's disease, thromboembolisms occurred in at least three patients. a causal connection could not be proven, but since the same adverse effects were seen in trials with a similar antibody (hu5c8), the trials were halted. the drug was developed by idec pharmaceuticals corporation.